Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
SWOG Cancer Research Network
Pfizer
PrECOG, LLC.
Institut Paoli-Calmettes
Guangdong Provincial People's Hospital
Abramson Cancer Center at Penn Medicine
Fudan University
Fundación GECP
University of Washington
Sichuan University
Sichuan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Krystal Biotech, Inc.
University Hospital, Essen
Trans Tasman Radiation Oncology Group
Incyte Corporation
West China Hospital
Sun Yat-sen University
SWOG Cancer Research Network
University of Kentucky
Hoosier Cancer Research Network
Taproot Health
Tang-Du Hospital
Capital Medical University
Shanghai Pulmonary Hospital, Shanghai, China
Second Affiliated Hospital of Guangzhou Medical University
Sun Yat-sen University
Celldex Therapeutics
The First Hospital of Jilin University
Swiss Cancer Institute
The First Hospital of Jilin University
Shanghai University of Traditional Chinese Medicine
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Sykehuset i Vestfold HF
Zhejiang Cancer Hospital
Spectrum Pharmaceuticals, Inc
Abramson Cancer Center at Penn Medicine
H. Lee Moffitt Cancer Center and Research Institute
Ain Shams University
The First People's Hospital of Lianyungang
Bristol-Myers Squibb
Roswell Park Cancer Institute
Centre Francois Baclesse
Shanghai University of Traditional Chinese Medicine
Alliance for Clinical Trials in Oncology
ChineseAMS
AHS Cancer Control Alberta
University of Chicago
National Cancer Institute (NCI)